Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Trivalent Subunit Rotavirus Vaccine in Infants and Toddlers
NCT05621655Phase 2Active, not recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant trivalent subunit rotavirus vaccine in rotavirus infection and rotavirus gastroenteritis (12 arms), sponsored by MAXVAX Biotechnology. Primary endpoints: Incidence of adverse events, Geometric Mean Titers of anti-P[4], anti-P[6], anti-P[8] rotavirus IgA and 5 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
recombinant trivalent subunit rotavirus vaccine
03
Conditions
rotavirus infectionrotavirus gastroenteritis
Beyond the preview
Go deeper on NCT05621655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621655.